These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 31030756)
1. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide. Zhang Y; Zhang M; Tan L; Pan N; Zhang L Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756 [TBL] [Abstract][Full Text] [Related]
2. Development of a Synthetic Heparin Pentasaccharide: Fondaparinux. Walenga JM; Fareed J; Jeske WP; Bıck RL; Samama MM Turk J Haematol; 2002 Jun; 19(2):137-50. PubMed ID: 27264755 [TBL] [Abstract][Full Text] [Related]
4. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668 [TBL] [Abstract][Full Text] [Related]
5. Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism. Robinson DM; Wellington K Am J Cardiovasc Drugs; 2005; 5(5):335-46. PubMed ID: 16156690 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Samama MM; Gerotziafas GT Thromb Res; 2003 Jan; 109(1):1-11. PubMed ID: 12679126 [TBL] [Abstract][Full Text] [Related]
8. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery. Tran AH; Lee G Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815 [TBL] [Abstract][Full Text] [Related]
9. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
10. Fondaparinux (Arixtra): a new anticoagulant. Giangrande PL Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373 [TBL] [Abstract][Full Text] [Related]
11. Heparin: An essential drug for modern medicine. Hao C; Xu H; Yu L; Zhang L Prog Mol Biol Transl Sci; 2019; 163():1-19. PubMed ID: 31030744 [TBL] [Abstract][Full Text] [Related]
12. Clinical and experimental experience with factor Xa inhibitors. Viles-Gonzalez JF; Gaztanaga J; Zafar UM; Fuster V; Badimon JJ Am J Cardiovasc Drugs; 2004; 4(6):379-84. PubMed ID: 15554723 [TBL] [Abstract][Full Text] [Related]
13. Fondaparinux Sodium: Recent Advances in the Management of Thrombosis. Bauersachs RM J Cardiovasc Pharmacol Ther; 2023; 28():10742484221145010. PubMed ID: 36594404 [TBL] [Abstract][Full Text] [Related]
14. Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review. Nijkeuter M; Huisman MV Curr Opin Pulm Med; 2004 Sep; 10(5):338-44. PubMed ID: 15316429 [TBL] [Abstract][Full Text] [Related]
15. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis. Bauer KA Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577 [TBL] [Abstract][Full Text] [Related]
16. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Turpie AG Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281 [TBL] [Abstract][Full Text] [Related]
17. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors. Nutescu EA; Helgason CM Pharmacotherapy; 2004 Jul; 24(7 Pt 2):82S-87S. PubMed ID: 15317403 [TBL] [Abstract][Full Text] [Related]